Select Page

Investor Information

At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.

Disclosure Under Regulation 30

ParticularsDate
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingFebruary 03, 2023
Stock Exchange Letter Disclosure of Earnings Call Audio RecordingFebruary 01, 2023
Outcome of Q3 Board MeetingJanuary 31, 2023
Agreement to Acquire Concert Pharmaceuticals Inc.January 19, 2023
Sun Pharma to Acquire Concert Pharmaceuticals IncJanuary 19, 2023
Sustainability Report 2021-22December 23, 2022
Update on Halol facility - Additional detailsDecember 08, 2022
Update on Halol FacilityDecember 08, 2022
Update on US FDA Inspection at Mohali FacilityNovember 08, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingNovember 08, 2022
Outcome of Board MeetingNovember 01, 2022
Stock Exchange Letter Disclosure of Earnings Call Audio RecordingNovember 01, 2022
Update on Acquisition of UractivTM PortfolioSeptember 28, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingSeptember 17, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingSeptember 03, 2022
Proceedings of 30th AGM and intimation of Change in the Board of DirectorsAugust 29, 2022
Chairman’s Speech at 30th AGM of the CompanyAugust 29, 2022
Update on US FDA Inspection at Mohali FacilityAugust 13, 2022
Update on US FDA Inspection at Halol facilityAugust 13, 2022
Retirement of ChairmanAugust 03, 2022
Cessation of Compliance OfficerMay 31, 2022
Approval of Scheme of AmalgamationMay 30, 2022
Appointment of Lead Independent Director/ Re-appointment of DirectorsMay 30, 2022
Update on US FDA Halol InspectionMay 10, 2022
Top